Image Analysis Group (IAG), a leader in clinical trial imaging and AI-enhanced biomarkers, is broadening its footprint in the United States by establishing a new office in Cambridge, Massachusetts. This strategic move positions IAG closer to the heart of biotechnology and pharmaceutical industries, particularly in the Boston area, enabling the company to better cultivate partnerships and offer local support for clinical trials in this vibrant region.
The Cambridge office is set to bolster IAG’s efforts across various therapeutic domains, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic, and metabolic diseases. By situating its operations in this key location, IAG aims to collaborate more effectively with sponsors and contract research organizations engaged in Phase I–III clinical trials and imaging-intensive development initiatives. Additionally, the company plans to generate employment opportunities locally, with anticipated hiring in clinical imaging operations, data science, regulatory support, and business development within the next 12–24 months.
From this new site, IAG will deliver comprehensive imaging services, including consultation for clinical trial design, optimization of imaging protocols, centralized image analysis, and regulatory-compliant data delivery. The company believes that embedding itself in the Boston life-sciences ecosystem will enhance collaboration with a range of stakeholders, such as biotechnology firms, pharmaceutical companies, academic institutions, and clinical research centers.
Globally, IAG facilitates clinical trials across North America, Europe, and the Asia-Pacific region, partnering with pharmaceutical, biotechnology, and medtech companies, as well as contract research organizations, for multi-center studies. Its international operations are structured to ensure standardized imaging protocols, centralized data harmonization, and uniform imaging analysis across global trials.
Founded in 2007 and headquartered in London, Image Analysis Group operates as an imaging Clinical Research Organization (iCRO). The company supports pharmaceutical, biotechnology, and medical technology sectors with imaging-based clinical trial endpoints. IAG is active in fields such as oncology, inflammatory disease, musculoskeletal, cardiometabolic, and rare diseases, leveraging its DYNAMIKA™ platform for AI-driven image analysis, centralized quality control, and real-time clinical trial management. For more information, visit their website at www.ia-grp.com or contact them via email at [email protected]. Press inquiries can be directed to Marie Fussell at +1 267-857-8638 or [email protected].
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.